[Hepatitis caused by various derivatives of erythromycin].
作者信息
Funck-Brentano C, Pessayre D, Benhamou J P
出版信息
Gastroenterol Clin Biol. 1983 Apr;7(4):362-9.
PMID:6347792
Abstract
摘要
相似文献
1
[Hepatitis caused by various derivatives of erythromycin].
Gastroenterol Clin Biol. 1983 Apr;7(4):362-9.
2
[Cholestatic hepatitis caused by erythromycin estolate].
Rev Clin Esp. 1985 Nov;177(8):420-1.
3
Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate.
Dig Dis Sci. 1982 Aug;27(8):701-4. doi: 10.1007/BF01393764.
4
[Erythromycin-induced hepatitis].
Cah Anesthesiol. 1987 May-Jun;35(3):237.
5
Erythromycin estolate-induced hepatitis. Ultrastructural study of liver.
N Y State J Med. 1979 Jan;79(1):87-9.
6
Selection of an oral erythromycin product.
Am J Hosp Pharm. 1980 Sep;37(9):1199-205.
7
FDA begins proceedings to remove erythromycin estolate from market.
FDA Drug Bull. 1979 Nov;9(5):26-7.
8
[Acute hepatitis caused by erythromycin esters (propionate and ethylsuccinate)].
Gastroenterol Clin Biol. 1983 Jan;7(1):100-1.
9
[Hepatitis due to erythromycin ethylsuccinate].
Gastroenterol Clin Biol. 1982 Dec;6(12):1044-5.
10
Risk-benefit equation for erythromycin estolate.
Am J Hosp Pharm. 1980 Feb;37(2):176, 180.
引用本文的文献
1
Adverse effects of macrolide antibacterials.
Drug Saf. 1993 Nov;9(5):346-64. doi: 10.2165/00002018-199309050-00004.
2
Drug-induced cholestasis.
Med Toxicol. 1987 Mar-Apr;2(2):112-60. doi: 10.1007/BF03260010.
3
Toxicity, uptake, and subcellular distribution in rat hepatocytes of roxithromycin, a new semisynthetic macrolide, and erythromycin base.
Antimicrob Agents Chemother. 1988 Oct;32(10):1541-6. doi: 10.1128/AAC.32.10.1541.
4
Comparative in vitro activity of A-56268.
Eur J Clin Microbiol Infect Dis. 1988 Dec;7(6):798-802. doi: 10.1007/BF01975054.
Zotero 插件